CLINICAL TRIAL: BARI 2D

临床试验：BARI 2D

• 批准号: 7951521
• 负责人: EUGENE Joseph BARRETT
• 金额: $ 4.87万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951521
• 关键词: Clinical Research; Clinical Trials; Clinical Trials Design; Computer Retrieval of Information on Scientific Projects Database; Coronary; Funding; Glycosylated hemoglobin A; Grant; Institution; Insulin; Insulin Resistance; Medical; Randomized Controlled Clinical Trials; Research; Research Personnel; Resources; Source; United States National Institutes of Health; diabetic patient

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multicenter randomized trial designed to determine in Type II diabetic patients with stable CAD: 1) the efficacy of initial elective coronary revascularization combined with aggressive medical therapy, compared to an initial strategy of aggressive medical therapy alone; and 2) the efficacy of providing more insulin versus reducing insulin resistance with a target HbA1c level of <7.0% for each strategy.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是一项多中心随机试验，旨在确定II型糖尿病患者的稳定CAD：1）与单独的侵略性药物治疗的初始策略相比，初始选举冠状动脉血运重建与积极的药物治疗相比，最初的选举冠状动脉血运重建的功效； 2）每种策略的目标HBA1C水平<7.0％，提供更多胰岛素与胰岛素耐药性的功效。